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Abstract
DNA damage activates checkpoint controls which block progression of cells through the division cycle. Several different
checkpoints exist that control transit at different positions in the cell cycle. A role for checkpoint activation in providing
resistance of cells to genotoxic anticancer therapy, including chemotherapy and ionizing radiation, is widely recognized.
Although the core molecular functions that execute different damage activated checkpoints are known, the signals that
control checkpoint activation are far from understood. We used a kinome-spanning RNA interference screen to delineate
signalling required for radiation-mediated retinoblastoma protein activation, the recognized executor of G1 checkpoint
control. Our results corroborate the involvement of the p53 tumour suppressor (TP53) and its downstream targets p21CIP1/WAF1
but infer lack of involvement of canonical double strand break (DSB) recognition known for its role in activating TP53 in
damaged cells. Instead our results predict signalling involving the known TP53 phosphorylating kinase PRPK/TP53RK and the
JNK/p38MAPK activating kinase STK4/MST1, both hitherto unrecognised for their contribution to DNA damage G1 checkpoint
signalling. Our results further predict a network topology whereby induction of p21CIP1/WAF1 is required but not sufficient to
elicit checkpoint activation. Our experiments document a role of the kinases identified in radiation protection proposing their
pharmacological inhibition as a potential strategy to increase radiation sensitivity in proliferating cancer cells.
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Introduction
DNA damage through exposure to ionising radiation (IR) is an
important tool in cancer therapy. Radiotherapy features in the
treatment of greater than 50% of all cancers and IR is considered the
most effective treatment option for inoperable solid tumours [1,2].
Although objective responses are frequent, long-term remission is
not often seen, and patients commonly relapse with tumour re-growth
following cessation of treatment [3]. Increasing evidence suggests that
the genetic makeup of tumours critically influence the IR-sensitivity of
cancer tissue and the duration of remission in therapies involving IR
[4]. Loss of either damage repair [5] or damage-inducible cell cycle
checkpoint control [6] enhances IR sensitivity, suggesting that both
repair efficacy and checkpoint activation confer radioprotection.
Other evidence indicates that preferential activation of checkpoint
control provides resistance to cancer stem cells [7]. Hence inhibition
of repair or checkpoint signalling has been proposed as a strategy for
enhancing the response of cancers to radiotherapy [8,9].
DNA damage-inducible cell cycle checkpoints transiently delay
cell cycle progression in proliferating cells, presumably providing
time for repair [10,11]. DNA damage checkpoint control arises at
multiple points of the cell cycle including late G1 (G1), intra S
phase, and the G2 phase [12]. Recent years have seen considerable
progress in elucidating signalling involved in the different types of
checkpoint control. Checkpoint kinases 1 and 2 (CHK1/2) are key
executors involved in delaying S and G2/M transit [13,14,15,16].
CHKs phosphorylate, and thus inhibit, the dual specificity
phosphatases CDC25B and A [17,18,19,20] required for activa-
tion of the CDK2 and CDK1 cyclin-dependent kinases which
drive DNA synthesis and entry of cells into M phase respectively.
Other work demonstrates involvement of MAPKAP-kinase2
(MK2) and MK2-dependent GADD45A biosynthesis [21,22],
and a role for the p53 tumour suppressor protein TP53 in the
maintenance of the G2 checkpoint response [23,24].
G1 checkpoint activation is thought to involve the retinoblas-
toma tumour-suppressor (RB1) and its paralogues. RB1 inhibits
the transcription of gene products required for S phase entry,
amongst them the CDK2 activating cyclins E and A [25], and it
stabilizes the CDK inhibitory proteins p27KIP1/CDKN1B and
p21CIP1/WAF1/CDKN1A [26]. Exposure of cells to IR leads to
accumulation of RB1 in its active, underphosphorylated form
[27,28]. G1 checkpoint activation in irradiated cells is likely to be
of dual significance. In response to DNA damage, G1 checkpoint
execution may delay progression of G1 cells from entering S phase
[29,30]. G1 checkpoint activation also underlies ‘‘adaptation’’,
which follows escape of damaged cells from G2 arrest [31,32].
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Considerable evidence indicates that RB1 loss favourably affects
the response of tumours to radiotherapy. Several clinical studies
report that absence of RB1 expression predicts treatment success
of therapies involving IR, as indicated by prolonged disease-free
survival and absence of distant metastasis [33,34,35,36]. RB1
mediates the proliferation block induced by a range of DNA
damaging agents and cells with RB1 loss show accelerated death
following DNA damage [29,37], suggesting that inhibition of
radiation-mediated RB1 activation could be a strategy for radio-
sensitization of RB1 positive cancers.
The current knowledge as to the signalling that instigates RB1
activation is incomplete and controversial [30,38,39,40]. Here we
describe results from a kinome-spanning cell-based screen aimed
at the unbiased identification of signalling required for RB1
activation by IR. We identify a group of kinases, hitherto largely
unrecognized for their involvement in this context. We character-
ize the mode by which they interact with the cellular IR response
and document their involvement in facilitating G1-arrest and
survival of IR-exposed cells.
Results
Identification of signalling required for IR–driven RB1
activation
To build a screening assay for signalling involved in radiation-
mediated RB1 activation we determined the circumstances under
which changes in RB1 phosphorylation arise in irradiated cells. We
used HCT116 colon-derived carcinoma cells which represent a
clinically relevant cancer type for radiation treatment and which
express wt RB1. A robust loss of RB1 phosphorylation is seen in
these cells between 16 and 24 hours after IR exposure, as indicated
by a reduced signal with a phosphorylation-selective antibody for
RB1 P-Ser608 (Figure 1A, signal quantification in Figure S1A, A9).
This response arose in HCT116 p53+/+ cells but not in isogenic
HCT116 p532/2 cells (Figure 1B) for signal quantification see
(Figure S1), indicating a critical contribution of TP53 signalling to
radiation-mediated RB1 activation. Loss of phosphorylation was
seen on other sites, including Ser780 and Ser795 (Figure 1C) and
RB1 accumulating in irradiated HCT116 cells had an increased
propensity for binding to E2F (Figure S1), indicating general loss of
RB1 phosphorylation, and functional activation in these cells.
Using the conditions established we developed a 96-well screening
assay (Figure 1D) based on quantitative immunofluorescent detection
of phosphorylated RB1 in fixed cells. The assay involved use of an
antibody selective for Ser780-phosphorylated (PS780) RB1, which
proved technically superior to antibodies for other sites in pilot
experiments, and determined the percentage of cells with significantly
lower than average signal intensity (POS-LoRBPS780) using high-
content single cell-based analysis (see Materials and Methods and
Figure S4). Transfection of HCT116 cells with siRNA pools targeting
TP53 or its downstream target CDKN1A/p21CIP1/WAF1 reduced
POS-LoRBPS780 values in these cells more than 6-fold, compared to
cells transfected with either a non-targeting siRNA (NT) or without
oligonucleotide addition (Mock) (Figure 1E), demonstrating the
capacity of the assay to report checkpoint loss following siRNA-based
knockdown of relevant signalling components.
To uncover unknown signalling required for IR-mediated RB1
activation we screened an siRNA collection targeting all human
kinases and additional accessory molecules (779 targets) involved
in phospho-proteome regulation (see Table S1 for list of targets).
Based on mean POS-LoRBS780 values derived from triplicate
runs 59 of the 779 targets reached z scores ,21.5 with 22 targets
scoring,22 (Figure 1F). To identify hits with substantial impact we
further graded targets scoring with z,21.5 on the magnitude by
which their respective siRNA pools prevented RB1-PS780 loss.
‘Strong’ targets reduced the mean POS-LoRBPS780 by 2-fold or
greater, ‘average’ hits led to a reduction of 2- to 1.6-fold and ‘weak’
hits reduced the average POS-LoRBPS780 between 1.6- and 1.4-
fold (see Table S1). In total this yielded 41 hits, with 12 scoring
‘strong’, 18 ‘average’ and 11 ‘weak’. In a screen run in parallel using
unirradiated cells none of these hits reached z-scores less than21.3
and the vast majority scored greater21 (Figure S1), indicating that
the observed radiation-resistant RB1 phosphorylation is not due to
target knockdown increasing RB1 phosphorylation in unchallenged
cells. Gene names, identifiers and screen data for these hits are listed
in the Table S1, alongside data for all targets screened.
Gene ontology and pathway association of hits
Amongst the hits identified was the TP53 target gene CDKN1A/
p21CIP1/WAF1 [41], predicted from our initial assessment as being
critical for RB1 activation, confirming screen performance. The
Ataxia telangiectasia mutated (ATM) double stand break (DSB)-
activated protein family kinases ATM and ATR, and the checkpoint
kinase family kinases CHK1 or CHK2, known to activate TP53
signalling as part of the canonical double stand DNA damage
response, did not score, even though these targets were represented
in the gene set screened, suggesting that this signalling plays no role
in eliciting activation of the checkpoint under investigation. To
address if this signalling is indeed unnecessary for RB1 activation
following IR we used pharmacological inhibitors for this signalling
space (Figure S2). Neither treatment with KU-5593, a selective
inhibitor of ATM/ATR, nor the CHK1 selective inhibitor
SAR020106 abolished the radiation induced loss of RB1 phosphor-
ylation, (Figure S2). As previously observed (Figure 1), radio-resistant
RB1 phosphorylation was seen in parallel samples where cells were
transfected with siRNA targeting TP53. Both Ku-5593 and
SAR020106 inhibited autocatalytic activity of CHK1 (Figure S2),
indicative that they were effective in blocking damage-driven signal
transduction in the cell line and at the dose used. Analysis of lysates
from cells treated with these inhibitors provided corroborating
evidence, revealing net loss of RB1 phosphorylation following IR
exposure comparable to that of Mock-treated cells. Together these
results corroborate the critical requirement of TP53 and p21CIP1/
WAF1 as the signal executing axis yet indicate that signalling distinct
from the canonical TP53 activating DSB signalling is involved in
controlling radiation-mediated RB1 checkpoint activation.
To obtain information as to the type of signalling that was
detected in the screen we probed for the association of the
identified hits with known signalling pathway ontology. To do so
we searched for representation of hits within defined pathways and
processes using the NIH Database for Annotation, Visualization
and Integrated Discovery (DAVID), http://david.abcc.ncifcrf.
gov/home.jsp. This revealed considerable representation within
MAPK and calcium signalling (Figure 2A) along with membrane
receptor signalling ontology in which both MAPK and calcium
signalling play a role. Overall, 23 of the 41 hits (57%) were
accounted for by these pathway categories. 18 hits (43%) were not
represented within the analysis output, indicating that the screen
also identified components that do not significantly cluster within
the pathways and processes considered in the database interro-
gated. A number of pathways although strongly represented in the
screened gene set were not reflected in the hit list, indicating
selectivity of the screen (Figure 2B).
To confirm validity of the hits and ensuing predictions, we
sought hit confirmation using individual siRNA duplexes. We
confined this analysis to hits that had scored as either strong or
average in the primary screen, regardless of whether they were
associated within defined pathway ontology or not.
Mechanism of G1 Radiation Checkpoint Activation
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When re-examined in this way, half of the strong hits (6 of 12) and
two hits from the weaker category confirmed with two or more
oligonucleotides (Figure 2C), together yielding 8 hits validating with
multiple oligonucleotides, representing the p53-related protein kinase
PRPK/TP53RK, the mammalian sterile 20-like MAPK pathway
component serine threonine kinase STK4/MST1, the cyclin
dependent kinase CDK4, the dual specificity tyrosine (Y)- phosphor-
ylation-regulated kinase DYRK1A, the glucose-phosphorylating,
glycolytic enzyme hexokinase HK1, the cyclic AMP-
dependent protein kinase, gamma catalytic subunit PRKACG and
p21CIP1/WAF1/CDKN1A. Real-time PCR (RT-PCR) analysis (Figure
S2) showed that treatment with the respective oligonucleotides led to
transcript knockdown in all instances. Corroborating our original
analysis, DAVID analysis confirmed representation ofMAPK (STK4,
and PRKACG) and calcium signalling components (PRKACG)
amongst the validated hits, as well as representation of hits that do not
group to the annotated pathway ontology (CDK4, DYRK1A, HK1,
p21CIP1/WAF1, PRPK).
Effect of target knockdown on IR-mediated p21CIP1/WAF1
expression
To explore how the various hits contribute to the radiation
response we examined the effects of their knockdown on the IR-
induced accumulation of p21CIP1/WAF1. As mentioned previously,
Figure 1. siRNA screen for gene products involved in IR-associated RB1 activation. A) Loss of RB1 phosporylation in IR exposed
cells. HCT116 cells exposed to 5 Gy ionising radiation (IR) or untreated (C) were analysed at the time indicated. Levels of RB1 with phosphorylation
on Ser608 (RB1-PS608), total RB1 (RB1) and TP53 were established by immunoblotting. B) Loss of RB1 phosphorylation is TP53-dependent.
TP53 positive (+/+) and isogenic TP53 null (2/2) HCT116 cells exposed to 5 Gy ionizing radiation (IR) or untreated (C) were analysed 24 hours post
irradiation. Levels of RB1-PS608, total RB1 and p21CIP1/WAF1 were established by immunoblotting. C) IR affects RB1 phosphorylation at multiple
sites. Immunoblots probing for levels of RB1-PS608, RB1-PS780, RB1-PS795 in irradiated (IR) or untreated (C) HCT116. To document RB1 specificity of
the signal cells transfected with siRNA duplexes targeting RB1 (RB(1) and RB(2)) or nontargeting control siRNA (NT) were analysed in parallel. Cells
were irradiated and harvested at 24 hours following IR. Actin was used as a loading control. D) siRNA screening strategy. HCT116 were reverse
transfected with siRNA library pools in a 96 well format, and irradiated, fixed and stained using anti RB1-PS780 antibody and Hoechst 33342 dye, with
timelines as indicated. Plates were analysed using an IN Cell Analyzer 3000 high content platform (GE) with sequential blue and green laser excitation.
A set number of cell objects per well were analyzed for nucleus-associated antibody fluorescence (green channel). Hoechst 3342 DNA staining (blue
channel) was used for object and compartment identification. Intensity profiles were generated and automatically gated to determine the
percentage of cells with sub-normal antibody fluorescence (POS-LoRBPS780) in individual wells. E) Radio-resistant RB1 phosphorylation in cells
with siRNA-mediated TP53-signalling knockdown. Assay set up was as described in D, siRNA pools for TP53, p21CIP1/WAF1 or a non-targeting
oligonucleotide (nt) were used for transfection. Error bars relate to variance in POS-LoRBPS780 values from triplicate wells. F) Primary screen
outcome. Z-score distribution for target screened. Z-scores were calculated for the mean POS-LoRBPS780 observed in triplicate wells and are plotted
in ranked order. Hits are shown colour-coded according to hit class within the Z-score distribution.
doi:10.1371/journal.pone.0031627.g001
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irradiation of cells induces expression of p21CIP1/WAF1 [41], and
the cyclin-dependent kinases (CDKs) responsible for phosphory-
lation of RB1 are inhibited by p21CIP1/WAF1 [42,43,44] providing
a potential mechanism by which IR treatment leads to the
accumulation of active RB1 in cells. Our results that siRNA
targeting p21CIP1/WAF1 leads to radiation-resistant RB1 phos-
Figure 2. Hit gene-ontology and pathway associations. A) Pathway representation within hit pool. Hits were analysed for pathway
association using the DAVID functional annotation tool (http://david.abcc.ncifcrf.gov/). B) Enrichment for gene ontology. Pathway association
was analysed for hits and input using DAVID. Pathway representation within hits is plotted against that for input targets. C) Hit validation. Hits
were assessed using individual oligonucleotides represented within the pool. The number of active oligonucleotides and level of response is
indicated. Hit classification was as for the screen.
doi:10.1371/journal.pone.0031627.g002
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phorylation (Figure 1E an d 2C) supports the critical role of this
gene in G1 checkpoint activation. We therefore hypothesized that
knockdown of at least some of the targets identified act by affecting
p21CIP1/WAF1 accumulation.
To test this hypothesis, we adapted the method for quantifying
antibody fluorescence for assessment of p21CIP1/WAF1 abundance.
To determine the percentage of p21CIP1/WAF1-positive cells (POS-
p21) we gated for nuclear signal intensity substantially higher than
the background fluorescence in cells with ablation of the
transcription regulator TP53, known to facilitate p21CIP1/WAF1
induction in irradiated cells [45] (Figure S4 and Material and
Methods). As expected IR treatment of cells led to a robust
increase in the percentage of cells with p21CIP1/WAF1 positivity at
16 hrs, the time when RB1 activation is first apparent, in either
Mock transfected cells or cells transfected with NT oligonucleotide
(Figure 3). A substantial and highly significant reduction in the
percentage of p21CIP1/WAF1 positive cells was seen upon
knockdown of three of the validated targets, PRPK/TP53RK,
the MAPK pathway component STK4/MST1 and CDK4
(Figure 3A, C). Notably, knockdown of the remaining three
targets, DYRK1A, HK1, and PRKACG, had minor and non-
significant effects (Figure 3A, C), although their knockdown
effectively prevented IR-induced loss of RB1 phosphorylation in a
parallel assessment (Figure 3B).
Figure 3. Effect of target knockdown on IR-mediated p21CIP1/WAF1 induction. A) Effect of target knockdown on p21CIP1/WAF1
positivity. HCT116 cells transfected with siRNA as indicated were irradiated (IR) or left untreated (control). Cells were assessed for p21CIP1/WAF1
positivity 16 hrs post IR. The percentage of cells with p21CIP1/WAF1 positivity relative to Mock-treatment (Lipid) is shown. Error bars represent the
variance of the mean of three biological replicates, run in triplicate. B) Modulation of RB1 phosphorylation by target knockdown. POS-
LoRBPS780 analysis was performed in parallel plates. Data points represent the means of triplicate technical replicates and are evaluated using hit
classification as for the screen. C) Statistical analysis. Paired t-tests results for data shown in A. D) Treatment interaction test. Targets that
yielded significant impairment of p21CIP1/WAF1 positivity were tested for evidence of interaction between radiation and target knockdown. Values
indicate the degree of antagonism experienced in IR exposed cells.
doi:10.1371/journal.pone.0031627.g003
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Knockdown of PRPK and STK4 also reduced p21CIP1/WAF1
positivity in the unirradiated cells (Figure 3A, C), indicating the
potential involvement of these kinases in signalling contexts
independent of IR challenge. Mathematical testing for an
interaction between knockdown of these targets and irradiation
(see Materials and Methods) provides evidence for a net antagonism
of target knockdown with IR-mediated p21CIP1/WAF1 accumulation
that is not explained by the reduction of p21CIP1/WAF1 expression in
unchallenged cells (Figure 3D). Hence although PRPK and STK4
promote p21CIP1/WAF1 positivity in an IR-independent context,
these genes in addition have a significant role in supporting a DNA
damage-associated increase in p21CIP1/WAF1 positivity.
Together our experiments suggest a significant involvement of a
group of the hits in facilitating p21CIP1/WAF1 positivity upon
irradiation. In contrast other hits must play a role in radiation
mediated RB1 activation unconnected to p21CIP1/WAF1positivity.
Effects on IR-mediated G1 arrest
Since DNA damage-induced activation of RB1 is thought to
promote cell cycle arrest in G1 [29,46] we tested if the identified
hits are required for this response. To assess cell cycle response we
used a GFP-tagged cell-cycle reporter that localizes to the nucleus
during G1 but redistributes to the cytoplasm as a consequence of
CDK2 activation and S phase entry [47]. Using HCT116 cells
with stable expression of this reporter we determined the
percentage of G1 cells following IR exposure and upon knockdown
of the various hits (Figure 4). Cells with a ratio of nuclear to
cytoplasmic fluorescence of two or greater were considered G1
(POS-G1, Figure S4 and Materials and Methods). As previously,
we used POS-LoRBPS780 analysis alongside this assessment to
monitor for siRNA performance (Figure 4B).
Knockdown of all targets led to loss of G1 cells when compared
to Mock (Lipid) treatment or treatment with NT oligonucleotide.
The cumulative data scored significantly in paired Student’s t-tests
in all instances except DYRK1A where, however, the calculated p-
value (0.08) strongly converged towards significance (Figure 4C).
None of the targets when knocked down caused significant
changes in the G1 content in non-irradiated cells (Figure 4A, C),
indicating the encoding genes do not act by affecting normal cell
cycle progression. Mathematical testing for interaction between
Figure 4. Effect of target knock down on G1 checkpoint activation. A) Effect of target knockdown on relative G1 positivity. HCT116
cells transfected with siRNA as indicated were irradiated (IR) or left untreated (control). Cells were fixed 16 hours later and assessed for the proportion
of cells in G1. The degree of G1 positivity relative to Mock-treated (Lipid) cells is shown. Error bars represent the variance from the mean of three
biological replicates, run in triplicate. B) Modulation of RB1 phosphorylation by target knockdown. POS-LoRBPS780 analysis performed in
parallel to A). Data points represent the means of triplicate technical replicates. C) Statistical analysis. Paired t-tests for data shown in A. D)
Treatment interaction test. Data were assessed for evidence of a interaction between radiation and target knockdown. Values indicate the degree
of antagonism experienced in IR exposed cells.
doi:10.1371/journal.pone.0031627.g004
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target knockdown and IR confirmed selective antagonism of G1
positivity in IR exposed cells as opposed to alteration of G1
positivity in unchallenged cells, supporting a significant role and
requirement for the identified hits in IR-mediated G1 checkpoint
activation. Inhibitors of canonical DSB signalling did not prevent
the accumulation of cells in G1 following IR exposure, consistent
with our earlier results (Figure S1) that such signalling is not
involved in RB1 activation, and hence may not participate in the
control of G1 checkpoint response (Figure S3).
Effect of target silencing on IR-associated cell survival
G1 checkpoint activation is thought to play an important role in
protecting cells against IR elicited death [6]. Importantly, loss of
G1 checkpoint activity was shown to exacerbate the loss of
checkpoint functions in S and G2/M phase of the cell cycle,
leading to radiation hypersensitivity of cells with such additional
defects [48,49,50,51,52]. We thus hypothesized that ablation of
the genes identified in the screen could lead to radio-sensitization
and that this may be potentiated by a loss of G2 checkpoint
signalling. To test these hypotheses we assessed whether silencing
of the identified targets might increase the sensitivity of tumour
cells to radiation, using a cell viability assay based on ATP
luminescence (Figure 5, Figure S5). To assess if survival loss
required (or was exacerbated) by G2 checkpoint loss we
simultaneously knocked down the checkpoint kinase CHK1, a
key signal transmitter in this checkpoint (Figure 5). As in previous
experiments we used parallel-transfected cells for assessment of
PS780 RB1 loss, to safe-guard against false negative scores caused
by lack of siRNA performance (Figure 5K; Figure S5).
An increased loss of viability, that scored significantly in
statistical tests, was seen with all targets. Exacerbation of survival
was either confined (STK4 and DYRK1A) or predominant
(PRPK and HK1) in cells in which CHK1 expression was
knocked down (Figure 5A–D), or equal (PRKACG and CDK4) in
both CHK1 perturbed and unperturbed cells (Figure 5E, F and L;
Figure S5). Knockdown of STK4, PRPK, HK1 and DYRK1A,
which exacerbated survival under condition of CHK1 knockdown,
mirrors the effects of RB protein knockdown, where, similarly,
enhanced viability loss is dependent upon CHK1 loss (Figure S6),
corroborating the prediction that G1 checkpoint control provides
radioprotection under conditions of G2 checkpoint loss. We note
that combined knockdown of RB1 and RBL1/p107 is required to
similarly exacerbate radiation response in these experiments, in
agreement with the frequently redundant functioning of these
proteins in many cell lineages and signalling contexts [53].
Knockdown of PRKACG or CDK4, where increased loss of
viability arises regardless of whether CHK1 function is perturbed
(Figure 5LandFigures S5) in turn reflects the effects of p21CIP1/WAF1 or
TP53 knockdown, or the knockdown of the DNA damage sensor
ATM (Figure 5H–I and L). It is known that TP53 and its effector
p21CIP1/WAF1, as well as ATM, significantly contribute to G2/M
checkpoint execution [23,54,55], explaining why additional CHK1
loss does not exacerbate the loss of viability. The similarity in
behaviour of PRKACG and CDK4 may indicate that these targets
likewise are required in G2 checkpoint signalling.
We also tested the response to knockdown of the identified
targets in TP53-perturbed backgrounds (Figure S7). None of the
targets yielded significantly enhanced viability loss here, (Figure
S7) although target dependent sensitization was seen in parallel
run assays using Mock-perturbed cells, in keeping with a signalling
scenario in which TP53 plays a central role.
Mathematical testing for interaction between radiation and
target knockdown (Figure 5N; Figure S5) corroborate that target
knockdown significantly synergized with IR treatment in reducing
cell viability for five of the targets (Figure 5N and Figure S5).
Consistent with our prior assessment knockdown of STK4, HK1
and PRPK, which yield enhanced viability loss in conjunction with
CHK1 perturbation, yielded substantially enhanced sensitization
in CHK1 perturbed cells as opposed to Mock-perturbed or
unperturbed cells (Figure 5M, N and Figure S5). Together our
experiments provide clear evidence for a modulation of radiation
response in cells following perturbation the G1 checkpoint
activating targets identified and highlight an interaction with G2
checkpoint competence for the majority of these.
Data consolidation for derivation of a G1 checkpoint-
signalling model
To consolidate our data into a signalling model we entered the
numerical observations from our analysis into the open access
software environment for statistical and graphic data analysis, R
(http://www.r-project.org/). Application of the default algorithm
for unsupervised clustering analysis sorted the different targets
broadly into two groups. One group containing PRPK and STK4,
CDK4 and p21CIP1/WAF1 (group I) co-clustered with TP53
knockdown, a second group containing DYRK1A, PRKACG
and HK1 (group II) aligned separately from the former (Figure 6A).
Using the grouping information along with the features established
by our experimental analysis, we assembled a signalling framework
built around the known axes involving TP53 activation,
consequential p21CIP1/WAF1 induction and resulting attenuation
of RB1 phosphorylation (Figure 6B). According to our experi-
mental results all targets within group I share the feature of being
required for p21CIP1/WAF1 positivity, predicting that their
knockdown either affects transcription of the p21CIP1/WAF1 gene,
or the subsequent production or accumulation of p21CIP1/WAF1
protein. In contrast, group II targets are not required for
accumulation of cells with p21CIP1/WAF1 positivity, suggesting a
network topology whereby p21CIP1/WAF1 is required but not
sufficient to attenuate RB1 phosphorylation and G1 checkpoint
arrest.
Discussion
Accumulation of RB1 in its active, underphosphorylated form is
known to arise in cells experiencing genotoxic stresses, concurrent
with arrest of cell cycle progression in such cells [56]. RB1, and in
some contexts its paralogues, have been shown to play a critical
role in promoting survival of cells exposed to genotoxic stress,
supporting a view whereby DNA damage-associated signalling
leading to RB1 activation protects cells from radiation-induced
death. We used a mechanism-based RNA interference screen to
identify kinase signalling required for the accumulation of active
RB1 in cells, and identify a group of gene products critically
required for RB1 activation and radiation-associated G1 arrest.
The majority of these gene products has not previously been linked
to IR signalling or G1 checkpoint control.
We found that several of these functions are required for the
accumulation of the CDK inhibitor p21CIP1/WAF1 in IR-exposed
cells. The transcription of p21CIP1/WAF1 is activated by TP53,
which itself is activated by genotoxic stress [54]. Knockdown of
p21CIP1/WAF1 or TP53 permits radio-resistant RB1 phosphoryla-
tion and prevents G1 arrest, and p21CIP1/WAF1 was a hit in the
screen, corroborating the critical contribution of this signalling.
Two of the screen hits, PRPK and STK4, encode kinases
previously linked to TP53 activation and p21CIP1/WAF1accumula-
tion, although neither has been linked to checkpoint activation or
sensitivity in IR challenged cells. PRPK has been shown to bind to
TP53 in vivo and along with its yeast homologue Bud32, can
Mechanism of G1 Radiation Checkpoint Activation
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Figure 5. Effect of target knockdown on radiation survival. A–I) Target knockdown affects survival of IR exposed cells. HCT116 cells
transfected with target siRNA alone or in combination with siRNA targeting CHK1. Cells were Mock-irradiated or irradiated with 2 Gy or 5 Gy and
viable cells quantified 5 days later. Data plotted are normalized to the respective untreated controls. Filled squares = combined target and CHK1
knockdown (Target/CHK1), open squares = CHK1 only (Li/CHK1), filled triangles = Target only (Target/NT), open triangles =Mock (Li/NT). Error bars
represent the variance from the mean from three technical replicates. K) Modulation of RB1 phosphorylation by target knockdown. Parallel
Mechanism of G1 Radiation Checkpoint Activation
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phosphorylate mammalian TP53 on S15 and S37 in vitro [57].
Phosphorylation of TP53 on these sites is known to result in
increased TP53 transcriptional activity [58], supporting an
assumption whereby PRPK plays a direct role in regulating
signalling through the TP53-p21
CIP1/WAF1
axis. A very recent report
[59] identified PRPK in a screen for sensitizers to spindle assembly
checkpoint activation showing that knockdown inhibited mitotic
slippage with adaptation, consistent with a role of this gene
product in G1 checkpoint activation. The second kinase, STK4, is
a component of the MAPK ontology, and is not known to directly
phosphorylate TP53 [60]. STK4 has been reported to act
upstream of the c-Jun N-terminal kinases (JNK1-3/MAPK8-10)
and p38/MAPK11-14 mitogen activated kinase family kinases
[61,62]. Both JNK and p38 kinases are known to phosphorylate
and activate TP53 [63,64]. Furthermore p38 family kinases are
known to become activated in response to IR and as being
required for IR-induced accumulation of p21CIP1/WAF1 [65], yet
the signalling that leads to their activation is not know. Other
recent work showed that STK4 activity promotes p21CIP1/WAF1
stability in a JNK-dependent manner [66] suggesting participation
of this kinase in signalling resulting in transcriptional as well as
posttranscriptional control of p21CIP1/WAF1. Our findings, in
concert with the current literature, places STK4 as acting through
the SAPK/JNK and p38 signalling MAP kinase cascades into
DNA damage driven G1 checkpoint activation. While it is possible
that the p21CIP1/WAF1 loss observed in cells with PRPK or STK4
loss is a consequence of checkpoint loss, rather than its cause, the
critical requirement of p21CIP1/WAF1 accumulation documented
by our work together with the known involvement of PRPK and
STK4 in the regulation of this CDK inhibitor make such an
interpretation less likely.
The canonical route leading to TP53 activation in cells upon
genotoxic insult involves ATM or ATR and their substrates
CHK1 and CHK2, which in turn facilitate TP53 phosphorylation
and activation [67,68,69]. As indicated in the results chapter, none
of these genes scored in the screen nor did their pharmacological
inhibition abolish G1 checkpoint activation, strongly supporting a
view whereby signalling implicating these components is not
involved in G1 checkpoint control. The implication of the TP53/
p21CIP1/WAF1 signalling hub in both S/G2 and G1 checkpoint
control, along with the documented requirement of PRPK and
STK4, suspected to affect this hub, in G1, proposes a model
whereby TP53/p21CIP1/WAF1 facilitates execution of multiple
checkpoints, but executor hub activation is controlled by unrelated
yet convergent signalling ontology (see Figure 6B).
STK4 and PRPK cluster with CDK4 as hits through their
similar propensity to reduce p21CIP1/KIP1 positivity in irradiated
cells. Identification of CDK4 in this screen is unexpected, as this
kinase is known for its role in promoting RB1 phosphorylation and
hence knockdown should lead to attenuation of the event [70].
Knockdown of the closely related and potentially redundant kinase
CDK6 did not confer radiation-resistant RB1 phosphorylation but
led to loss of RB1 phosphorylation in control and irradiated cells
(not shown and Table S1), in line with the perceived role of
CDK4/6 in driving RB1 inactivation and indicative of the critical
role of this kinase-group in driving RB1 phoshorylation in the
cells. It is possible that off-target activities of oligonucleotides led to
identification of CDK4 and this cannot be fully excluded, albeit
this target validated with two unrelated oligonucleotides. There is
no prior published evidence whereby CDK4 is required for the
induction or maintenance of p21Cip1/Kip1 expression. However,
CDK4 in complex with D cyclins can bind p21Cip1/Kip1 and it is
possible that this interaction stabilizes the CDK inhibitor.
Reduction in CDK4 could free cyclin D to activate kinases other
than CDK4, capable of phosphorylating RB1, an event that has
been seen in cells with CDK4/6 knockout cells [71], and this could
explain the radiation-resistant RB1 phosphorylation observed
upon CDK4 knockdown.
Several other gene products identified as hits in the screen did
not significantly impact p21CIP1/Waf1 accumulation, suggesting
that they support checkpoint control through mechanisms
independent of TP53 activation and p21Cip1/Kip1 expression.
They include HK1, PRKACG and the DYRK1A dual specificity
kinase. There is some evidence that mechanisms other than
p21CIP1/WAF1-mediated inhibition of the RB1 phosphorylating
CDKs may play a role in the DNA damage-associated activation
of RB1. For example there is published evidence for the activation
of an RB1-directed phosphatase [72] and the phosphorylation-
mediated degradation of cyclin D [73,74,75] in irradiated cells. It
is conceivable that HK1, PRKACG and DYRK1A act through
such alternative means.
In common between HK1 and PRKACG is their involvement
in driving oxidative glycolysis [76], with knockdown of either
enzyme predicted to cause cessation of this process. Identification
of HK1 and PRKACG in the screen could hence suggest that
glycolytic activity is required for G1 checkpoint activation
following genotoxic stress. Short-term treatment of cells with
Lonidamine, a selective inhibitor of glycolysis has recently been
associated with increased sensitivity to radiation [77], providing
corroborating evidence for the interaction of this process with
DNA damage response, and potentially checkpoint control.
We note that CDK4, as well as LATS2, a kinase that can
activate DYRK1A, was identified in a recently reported RNA
interference screen [78] searching for functions which overcome
proliferation inhibition following enforced expression of RB1 in
RB1 phosphorylation incompetent SAOS2 cells. It is conceivable
that knockdown overcame the RB1 phosphorylation incompe-
tence of SAOS2 cells, which is believed to result from high
expression of p16INK4A in combination with stabilization of the
p21CIP1/WAF1 paralogue p27KIP1. The functional analysis by
Tschoep leaves open whether LATS2 or CDK4 knockdown
operates by reinstating RB1 phosphorylation and Tschoep et al.
2011 did not identify other targets that scored positive in the
screen reported here.
Radiation affects cell cycle progression at multiple points of the
cell cycle. The mechanism underlying DNA damage related G2
and M phase checkpoint control has received considerable
attention resulting in increasingly detailed models for the signalling
involved [21,79]. The available knowledge as to signalling
involved in damage-associated G1 checkpoint activation is
comparatively scarce. Efforts towards delineation of signalling
leading to G2/M checkpoint activation may have been fuelled by
the recognition that this checkpoint is essential in cells with TP53
loss and thus the potential to uncover therapeutic opportunities in
POS-LoRBPS780 analysis was used to verify siRNA performance. L) Statistical analysis. Student t-test for cell viability data shown in A–I, (Li/NT vs
Targ/NT) probing for a significant effect of target knockdown in unperturbed cells, (Li/CHK1 vs Targ/CHK1) probing for a significant effect of target
knockdown in CHK1-perturbed cells, Target/NT vs Target/CHK1 probing for a significant effect of CHK1 knockdown in target-perturbed cells. M, N)
Treatment interaction. Assessment for evidence of interaction between radiation and target knockdown. Values represent the degree of net
synergism between target knockdown and IR in NT (M) or CHK1-perturbed (N) cell background.
doi:10.1371/journal.pone.0031627.g005
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Figure 6. Data consolidation. A) Data clustering analysis. Unsupervised clustering based on numerical observations. B) Signalling model.
Hits split into groups according to their role in the accumulation of the TP53 target p21CIP1/WAF1. Canonical double strand signalling components
(ATM, ATR, CHK1/2) affecting the TP53/p21CIP1/WAF1 axes in conjunction with S/G2 checkpoint activation do not affect G1 checkpoint function.
doi:10.1371/journal.pone.0031627.g006
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TP53 negative cancers [80]. However, nearly 70% of all cancers
express wt TP53, and demonstrate competence for DNA damage-
associated TP53 signalling [81]. Inhibition of the components
identified here may be a suitable therapeutic strategy to
compromise radiation survival of such cancers. The participation
of TP53, p21Cip1/Kip1 and the RB proteins in G1 checkpoint
control is recognized [79]. The identification of druggable kinases
required for IR-mediated RB1 activation reported here, to our
knowledge, represents the first systematic approach towards
discovery of targets for the manipulation of DNA damage-
associated G1 checkpoint activation.
Materials and Methods
Cell lines and Antibodies
IR was delivered using an AGO HS-MP1 x-ray set. Green
fluorescent protein (GFP)-tagged G1 cell cycle reporter encoding
the sub-cellular localization domain of human helicase B [47] was
purchased from GE Healthcare. CellTiter-GloH cell viability assay
was from Promega. Antibodies used were as follows; anti-RB1-P-
S608 (Serotec), anti-RB1-PS795 (Sigma), anti-RB1 (Pharmingen),
anti-TP53 (NeoMarkers), anti-p21CIP1/WAF1 (Upstate), anti-
GAPDH (Abcam), anti-ß-actin (Abcam), Chk1 G-4 sc8408 (Santa
Cruz), P-S296 Chk1 2349 S (Cell Signaling), P-S780 Rb 1182-1
(Epitomics). Secondary anti-mouse/rabbit Alexafluor 488/647
(Invitrogen) and secondary HRP-coupled anti-mouse/rabbit IgG
(PIERCE). HCT116 human colorectal cancer cells were obtained
from ATCC. HCT116 with stable expression of a GFP-tagged cell
cycle reporter were generated in house. HCT116 p53+/+ and
p532/2 isogenic cell lines were provided by the Vogelstein
laboratory. SAR020106 was obtained from Dr. Michelle Garrett,
Institute of Cancer Research and used at 1 mM, KU-55933 was
obtained form Tocris Bioscience and used at 10 mM.
Protein analysis
Cell lysates were prepared in HBS buffer (50 mM HEPES
pH 7.0, 250 mM NaCl, 0.2% Triton-X100, 1 mM DTT, 1 mM
EDTA, 1 mM NaF, 10 mM ß-glycerophosphate, 0.11mM
NaVO4 plus EDTA free protease inhibitors (Roche). SDS-
polyacrylamide gel electrophoresis followed standard procedures.
Proteins were transferred onto PVDF membranes (Millipore) then
probed with antibodies and HRP-coupled secondary antibodies
and exposed to ECL PlusTM reagent (GE Healthcare Sciences).
Glutathione-S-transferase (GST)-assisted pull downs used full-
length GST-fused E2F-1 with unfused GST as a control. Assays
were performed as detailed in [37].
RNA analysis
RNA was prepared using Trizol (Invitrogen) followed by
phenol/chloroform extraction. First strand cDNA synthesis was
performed using hexamer random primers (Promega). Quantita-
tive PCR (qPCR) based analysis was performed using the Precision
qPCR master-mix (PrimerDesign) with Taqman primers (Applied
Biosystems). Water was used instead of cDNA as background
control. An Applied Biosystems Prism Sequence Detection System
was used to measure relative gene expression from each sample.
High-throughput siRNA screening assay
HCT116 cells were reverse transfected in triplicate sets of 96-well
PackardView plates (Thermofisher) with siRNA from a kinome-
covering library (Dharmacon) in a one-gene, one-well format. Cells
were seeded at 8,000 cells/well and transfected using HiPerFect
lipid transfection reagent (Qiagen) at a fixed siRNA concentration
of 20 nM. Cells were exposed to 5 Gy IR 24 hours following
transfection and fixed at 48 hrs using 3.7% formaldehyde/PBS
(Sigma) for 10 min. Fixed cells were permeabilised using 0.1%
Triton X-100 (Sigma) in TRIS-buffered Saline (TBS), blocked in
5% skimmed milk powder in TBS/0.1% Tween-20 (Sigma) and
probed with anti-RB1-PS780 rabbit monoclonal antibody (Epi-
tomics) followed by Alexafluor 488 secondary antibody containing
2 mM Hoechst 33258, diluted in 5% skimmed milk powder in
TBS/0.1% Tween-20. The intensity of fluorescent nuclear signal in
a minimum of 1500 individual cells was determined using an IN
Cell Analyzer 3000 high content image analyzer (GE Healthcare).
Data were exported into Microsoft Excel, which was used for data
handling and analysis. Intensity profiles were established for
individual cell data and gated for the percentage of cells displaying
low levels of RB1-PS780 loss (POS-LoRBPS780 value – see
Figure 4A). All plates contained triplicate positive controls
(p21CIP1/WAF1 siRNA) and triplicate Mock controls (lipid only). Z-
factor calculations relating to these controls were applied to evaluate
the quality of all plates. [82]. Plate sets were rejected and rerun
where any yielded z-prime ,0.2.
G1 reporter assay and p21CIP1/WAF1 positivity
HCT116 cells stably expressing a green fluorescent protein
(GFP)-tagged G1 cell cycle reporter were generated by transfection
of the reporter alongside a puromycin encoding plasmid (pBabe-
Puro). Transfected cultures were subjected to puromycin selection
followed by fluorescence activated cell sorting for GFP positivity.
siRNA transfection, treatment and fixation were as for screening.
Cells were imaged to determine the G1 cell cycle component by
determining the nuclear and cytoplasmic GFP signal ratio for a
given cell. At a minimum 1500 individual cells were imaged for each
data point. The calculated ratio of cytoplasmic: nuclear fluorescence
was gated and the percentage of cells per well determined that had a
signal intensity ratio .2, (POS-G1 value), see (Figure S4). To
quantify p21CIP1/WAF1 positivity, cells were stained with anti
p21CIP1/WAF1 primary antibody, followed by Alexafluor 488
secondary antibody. Nuclear fluorescence for .1500 cells was
determined, and cells with objective p21CIP1/WAF1 positivity (POS-
p21) identified by gating, see (Figure S4)
Cell survival assay
HCT116 cells were reverse transfected with siRNA and divided
three ways into triplicate plates at a seeding density of 2,666 cells/
well. A plate at a seeding density of 8000 cells/well for determining
POS-LoRBPS780 POS was generated in parallel. 24 hours
following transfection plates were irradiated with 5 Gy IR, 2 Gy
IR or left untreated. Plates for survival assessment were incubated
for a further 5 days. The amount of viable cells per well was
assessed using CellTiter-GloH. Plates for POS-LoRBPS780
assessment were fixed and processed as for the screen. In addition
to silencing the various targets we included siRNA duplexes
targeting PLK1, a gene previously shown as being required for
viability of Ras-transformed cells [83], to provide a positive control
for detecting viability loss.
Statistics
Z-prime calculations were done using 12(3(sp+sn)/(mp2mn)
with p = plate internal positive control or library candidate siRNA,
n = plate internal negative controls, s= standard deviation,
m=mean. All data are expressed as normalized means 6 SD
from at least three independent experiments unless otherwise
stated. Z-scores, describing the distance from the target mean to
the population mean in units of the standard error, were calculated
using standard Z-test statistics. Gene clustering was performed
using the heatmap function in ‘R’ statistical package (http://www.
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Rproject.org), using the normalized means from three individual
experiments for input.
Data from the p21CIP1/WAF1 analysis and G1 reporter assays
were tested using Student’s paired t-test. Tests for interaction
between target knockdown and treatment were performed as
described [84]. Briefly, the individual effect of target knockdown
and treatment was considered. The impact of target knockdown in
the absence of IR (Rc) compared to Mock knockdown in the
absence of irradiation (Cc) is designated Rc/Cc. The impact of
irradiation on Mock-transfected cells is designated CIR/Cc. From
these the expected combined response of target knockdown and
IR is derived by (Rc/Cc*Cx/Cc). The degree (index) of
interaction, either positive (sensitization) or negative (antagonism),
is calculated by subtracting the observed combined effect of IR
and target knockdown Rx/Cc form the expected interaction,
(Rc/Cc*CIR/Cc)2(RIR/Cc), where C=Mock-transfected, R=
target RNAi tansfected, IR = irradiated, c = untreated. An interac-
tion is considered antagonistic if the effect in CIR exceeds that in
RIR, and synergistic when the effect in RIR exceeds that in CIR.
Supporting Information
Figure S1 Modification of RB1 activity by IR. A), A9)
Signal quantification for results in Figure 1A. Charts depict
raw background corrected signal for P-S608 RB1 or relative signal
intensity relative to that of pan RB1 in the same samples.
Quantification was performed using electronic scans produced
from primary autoradiograms. Data were analysed using ImageJ
(http://rsbweb.nih.gov/ij/). B), B9) Signal quantification for
results in Figure 1B. Charts depict raw background corrected
signal for P-S608 RB1, or P-S608 RB1 signal relative to that of pan
RB1 in the same samples. Quantification and analysis was
performed as in A.C) IR activates RB1 E2F-binding capacity.
Lysates from IR treated (IR) and control (C) HCT116 cells were
incubated with GST-E2F-1 or unfused GST proteins, coupled to
Glutathione-Sepharose beads. Material retained on the beads was
probed for the presence of RB1 using immunoblotting. Immunoblot
analysis of input lysate indicating reduced RB1-PS780 in IR
exposed cells. Note increased amount of RB1 signal in pull-down
from IR exposed cells. D) Effect of gene knockdown on RB1
phosphorylation in irradiated and control cells. Z-scores
for POS-LoRBPS780 in untreated and irradiated cells.
(TIF)
Figure S2 Cellular response to target inhibition. A) IR
dependent RB1 activation following pharmacological
inhibition of double stand break signalling. HCT116 cells
seeded in 96 well dishes were treated with CHK1 selective
inhibitor SAR020106 (1 mM) or the ATM/ATR selective
inhibitor KU-55933 (10 mM) for 5 hrs prior to exposure to as
indicated. Transfection with siRNA for p53 served as a positive
control. NT denotes transfection with NT oligonucleotide,
MOCK defers to mock transfected cells. Plates were processed
for assessment 24 hrs post IR as for Figure 1E. B) IR dependent
CHK1 activation following inhibition of double strand
break signalling. HCT116 seeded in 6 well dishes and treated
in parallel to A) were lysed and analysed for CHK1 autophos-
phorylation activity. C) Signal quantification for results in
Figure S2B. Charts depict background corrected signal for P-
S296 CHK1 relative to pan CHK1 in the same samples. Signal
detection involved infrared fluorophore-coupled secondary anti-
bodies with signal quantification using a Li-COR Odyssey infrared
imager. D) IR dependent RB1 phosphorylation change
following pharmacological inhibition of double strand
break signalling. Levels of Ser780 phosphorylated RB1 (RB1-
P-S780) and total RB1 (RB1) were established 16 hrs post
irradiation by immunoblotting. E) Signal quantification for
results in Figure S2D. Charts depict background corrected
signal for P-S780 CHK1 relative to pan RB1 in the same samples.
Signal detection and quantification was as for Figure S2C. F)
Active siRNA species deplete target mRNA in transfected
cells. HCT116 cells were transfected with single siRNA oligonu-
cleotides as indicated and treated with 5 Gy of IR. RNA was
isolated 16 hrs post IR exposure. Transcripts were quantified using
Taqman RT/qPCR. Data were normalized against GAPDH.
Levels relative to those in cells transfected with NT siRNA are
shown. Error bars represent the variance from the mean of triplicate
technical replicates. Genes analysed were CDK4, DYRK1A, HK1,
SPHK2, STK4, PRPK or p21CIP1/WAF1.
(TIF)
Figure S3 Effect of double stand break signalling
inhibition on G1 checkpoint activation. HCT116 cells
seeded in 96 well dishes were treated with CHK1 selective
inhibitor SAR020106 (1 mM) or the ATM/ATR selective
inhibitor KU-55933 (10 mM) for 5 hrs prior to exposure to IR.
Transfection with siRNA for p53 served as a positive control. NT
denotes transfection with NT oligonucleotide, MOCK refers to
mock transfected cells. Data shown are derived though multiplex
analysis of experiments shown in Figure S2A. Data assessment was
as for Figure 4A.
(TIF)
Figure S4 Fixed-cell-assay data evaluation methodolo-
gy. A) POS-LoRBS780, determining the fraction of cells with
low RB1-PS780 signal relative to the total number of cells
measured. B) POS-p21, determining the fraction of cells with
objective p21CIP1/WAF1 positivity relative to the total number of
cells measured. C) POS-G1, determining the fraction of cells with
objective G1 positivity relative to the total number of cells
measured. Data evaluation relied upon gating for responders
based on histogram differences between negative (non-targeting)
and positive control (control target), run within the same plate.
Example positive (ve+) and negative (ve-) histograms for the
different assessments used in the reported work are shown.
(TIF)
Figure S5 Effect of target knockdown on radiation
survival in unperturbed backgrounds. A–G) Effects of
target kockdown on survival of IR exposed cells. HCT116
cells transfected with target siRNA were irradiated with 2 or 5 Gy,
or left untreated (control). Viable cells were quantified 5 days after
IR. Data are normalized to the untreated controls. Filled
triangles = target (Target), open triangles =Mock (Li). Error bars
represent the variance from the mean of three biological replicates,
run in triplicate each. H) Modulation of RB1 phosphoryla-
tion by target knockdown. Parallel POS-LoRBPS780 analysis
was used to verify siRNA performance. I) Statistical analysis:
Student t-test for data shown in A–G. Note highly significant
change in survival for PRKACG (***) and PRPK (**), with HK1
and p21CIP1/WAF1 strongly converging towards significance
(p,0.05). K) Treatment interaction. Data were assessed for
evidence of interaction between radiation and target knockdown.
Values represent the degree of synergism experienced in IR
exposed cells.
(TIF)
Figure S6 Effect of RB knockdown on radiation surviv-
al. A–E) RB family knockdown affects survival of IR
exposed cells. HCT116 cells transfected with oligonucleotides
targeting retinoblastoma family proteins either alone, or in
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combination with siRNA targeting CHK1. siRNA targeting
p21CIP1/WAF1 and non-targeting (NT) oligonucleotides were run
alongside for control. Cells were irradiated with 2 or 5 Gy or left
untreated and viable cells were quantified 5 days following IR
exposure. Data are normalized to the respective untreated
controls. Open triangles =Mock (Li/NT), open squares =CHK1
only (Li/CHK1), filled triangles = target only (target/NT), filled
square = combined target and CHK1 knockdown (target/CHK1).
Error bars represent the variance from the mean from three
technical replicates. F) Modulation of RB1 phosphorylation
by target knockdown. Parallel POS-LoRBPS780 analysis was
used to verify siRNA performance. G) Statistical analysis:
Student t-test for data shown in A–I. H) Treatment interac-
tion. Data were assessed for evidence of interaction between
radiation and target knockdown. Values represent the degree of
net synergism experienced in IR exposed cells in either Mock-
perturbed (NT) or CHK1-perturbed background.
(TIF)
Figure S7 Interaction of p53 perturbation on survival of
cells with target knockdown. A–G) Effects of target
kockdown on survival of IR exposed cells. HCT116 cells
were transfected with target siRNA alone or in combination with
siRNA targeting p53. Cells were treated with IR (5 Gy or 2 Gy) or
left untreated (control). Viable cells were quantified 5 days after
IR. Data are normalized to the untreated controls. Error bars
depict the variance from the mean for three technical replicates.
Filled square = combined target and p53 knockdown (target/p53)
filled triangles = target only (target/NT), open triangles =Mock
(Li/NT). H)Modulation of RB1 phosphorylation by target
knockdown. Parallel POS-LoRBPS780 analysis, verifying
siRNA performance. I, K) Treatment interaction. Data were
assessed for evidence of interaction between radiation and target
knockdown. Values represent the degree of net synergism
experienced in IR exposed cells. Note absence of significant
synergy in p53-perturbed backgrounds.
(TIF)
Table S1 Screen data. Target official gene symbol in
alphabetical order; average POS-LoRBPS780 (Average), variation
from the mean for n= 3 replicates (Standard Deviat) and Z-score
statistics calculated from the average POS-LoRBPS780 (Z-score)
are shown for each target.
(PDF)
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